1-11 of 11
Daniel P. Petrylak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Daniel P. Petrylak, Bernhard J. Eigl, Saby George, Elisabeth I. Heath, Sebastien J. Hotte, David D. Chism, Lisle M. Nabell, Joel Picus, Susanna Y. Cheng, Leonard J. Appleman, Guru P. Sonpavde, Alicia K. Morgans, Pourya Pourhosseini, Ruishan Wu, Laura Standley, Ruslan Croitoru, Evan Y. Yu
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF11.
https://doi.org/10.1158/1078-0432.CCR-22-3627
Published: 28 November 2023
View article titled, Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Open the PDF for Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

Emmanuel S. Antonarakis, Sumit K. Subudhi, Christopher M. Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason M. Hafron, Helen M. Wilfehrt, Matthew Harmon, Nadeem A. Sheikh, Neal D. Shore, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2426–2434.
https://doi.org/10.1158/1078-0432.CCR-22-3832
Published: 05 July 2023
View article titled, Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Open the PDF for Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials in another window
Includes: Supplementary data
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer

Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel, III, Kobe C. Yuen, Asim Datye, Andrew J. Armstrong, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4746–4756.
https://doi.org/10.1158/1078-0432.CCR-21-0063
Published: 01 September 2021
View article titled, A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

Johann S. de Bono, Mark T. Fleming, Judy S. Wang, Richard Cathomas, Manuel Selvi Miralles, John Bothos, Mary Jane Hinrichs, Qu Zhang, Peng He, Marna Williams, Anton I. Rosenbaum, Meina Liang, Kapil Vashisht, Song Cho, Pablo Martinez, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3602–3609.
https://doi.org/10.1158/1078-0432.CCR-20-4528
Published: 01 July 2021
View article titled, Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Open the PDF for Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John Powderly, Lauren C. Harshman, Paul Conkling, Jean-Pierre Delord, Michael Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, III, Sanjeev Mariathasan, Carol O'Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3360–3369.
https://doi.org/10.1158/1078-0432.CCR-20-1981
Published: 15 June 2021
View article titled, Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Open the PDF for Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study in another window
Includes: Supplementary data
Journal Articles

Abstract A23: The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial cancer

Christopher J. Hoimes, Jonathan E. Rosenberg, Daniel P. Petrylak, Anne-Sophie Carret, Amal Melhem-Bertrandt, Thomas W. Flaig
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): A23.
https://doi.org/10.1158/1557-3265.BLADDER19-A23
Published: 03 August 2020
View article titled, Abstract A23: The EV-103 Trial: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for patients with locally advanced or metastatic urothelial cancer
Journal Articles

Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival

Emmanuel S. Antonarakis, Eric J. Small, Daniel P. Petrylak, David I. Quinn, Adam S. Kibel, Nancy N. Chang, Erica Dearstyne, Matt Harmon, Dwayne Campogan, Heather Haynes, Tuyen Vu, Nadeem A. Sheikh, Charles G. Drake
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4662–4671.
https://doi.org/10.1158/1078-0432.CCR-18-0638
Published: 01 October 2018
View article titled, Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival
Open the PDF for Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival in another window
Includes: Supplementary data
Journal Articles

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Josep M. Piulats, Hardev S. Pandha, Daniel P. Petrylak, Fred Saad, Luis Miguel A. Aparicio, Shahneen K. Sandhu, Peter Fong, Silke Gillessen, Gary R. Hudes, Tao Wang, Judith Scranton, Michael N. Pollak
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1925–1934.
https://doi.org/10.1158/1078-0432.CCR-13-1869
Published: 31 March 2014
View article titled, Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer in another window
Journal Articles

The Novel Antimicrotubule Agent Cryptophycin 52 (LY355703) Induces Apoptosis via Multiple Pathways in Human Prostate Cancer Cells

Lisa Drew, Robert L. Fine, Tamara N. Do, Geoffrey P. Douglas, Daniel P. Petrylak
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (12): 3922–3932.
Published: 01 December 2002
View article titled, The Novel Antimicrotubule Agent Cryptophycin 52 (LY355703) Induces Apoptosis via Multiple Pathways in Human Prostate Cancer Cells
Open the PDF for The Novel Antimicrotubule Agent Cryptophycin 52 (LY355703) Induces Apoptosis via Multiple Pathways in Human Prostate Cancer Cells in another window
Journal Articles

Rapid in Vivo Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging

Richard P. Kline, Ed X. Wu, Daniel P. Petrylak, Matthias Szabolcs, Philip O. Alderson, Myron L. Weisfeldt, Paul Cannon, Jose Katz
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2146–2156.
Published: 01 June 2000
View article titled, Rapid <em>in Vivo</em> Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging
Open the PDF for Rapid <em>in Vivo</em> Monitoring of Chemotherapeutic Response Using Weighted Sodium Magnetic Resonance Imaging in another window